Blepharitis
Drug research and approvals for blepharitis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 18, 2026, 5 studies of blepharitis are recruiting on ClinicalTrials.gov, and Health Canada has authorized 0 drug trials for it since 2013.
- Recruiting worldwide: 5
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 0
Recruiting now
Newest start dates first, of 5 recruiting on ClinicalTrials.gov ↗- Ocular Dysbiosis in Eyelid DiseaseNCT07869498 · Not reported · Brent Kramer · starts Aug 7, 2026
- Evaluation of the Safety and Efficacy of GLK-321 in Subjects With Demodex BlepharitisNCT07400965 · Phase 2 · Glaukos Corporation · starts Dec 5, 2025
- Photobiomodulation With REd vs BluE Light (REBEL)NCT06371300 · Not applicable · Aston University · starts May 1, 2024
- Development of a Mobile Terminal-Based Intelligent Detection System for Multiple Anterior Segment Diseases of the EyeNCT07634913 · Not reported · Zhongshan Ophthalmic Center, Sun Yat-sen University · starts Dec 12, 2023
- Evaluation of SUMMIT BRUSH in Treatment of BlepharitisNCT04603222 · Not applicable · University of Notre Dame · starts Jul 21, 2020
Drug pipeline
1 approved, 6 in phase 3, 4 in phase 2, 2 in phase 1 or earlier; from ChEMBL's drug indications, furthest stage reached for this conditionApproved: Gentamicin
- Azithromycin
- Phase 3 Bacterial 70S ribosome inhibitor
- Lotilaner
- Phase 3 Ectoparasiticide
- Dexamethasone
- Phase 3 Glucocorticoid receptor agonist
- Metronidazole
- Phase 3 DNA inhibitor
- Tobramycin
- Phase 3 70S ribosome inhibitor
- Ivermectin
- Phase 3 Glutamate-gated chloride channel modulator
- Doxycycline anhydrous
- Phase 2 Matrix metalloproteinase 7 inhibitor
- Povidone
- Phase 2
- Loteprednol etabonate
- Phase 2 Glucocorticoid receptor agonist
- Fluticasone propionate
- Phase 2 Glucocorticoid receptor agonist
- Anakinra
- Phase 1 Interleukin-1 receptor antagonist
- Terpin
- Phase 1
How its trials ended
68 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 18 whose ending is known, 67% met their primary endpoint, 0% missed it and 33% stopped early.
- Completed, result not reported3146%
- Met its primary endpoint1218%
- Status unknown1015%
- Ongoing913%
- Stopped: other or unclear69%
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA